FDA Nod For AGIO's AML Drug, 2nd Neupogen Biosim Gets Green Light, BGNE On Watch

Today's Daily Dose brings you news about FDA approval of Agio's Tibsovo for refractory acute myeloid leukemia; BeiGene's encouraging preliminary topline results from its pivotal phase II trial of Tislelizumab in relapsed/refractory classical Hodgkin's lymphoma, and U.S. regulatory nod for Pfizer's fourth biosimilar.

from RTT - Biotech https://ift.tt/2LelU34
via IFTTT